Micronutrient Supplement Effects on Cognitive Outcomes in Post-Acute TBI
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03032302 |
Recruitment Status :
Completed
First Posted : January 26, 2017
Last Update Posted : October 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Traumatic brain injury (TBI) refers to neuronal damage occurring as the result of an external force being applied to brain tissue. In the United Kingdom annual figures (2013-2014) show 449,000 hospital admittances with a diagnosis of head injury with males up to five times more likely to sustain a head injury than females. Traumatic brain injury (TBI) causes life-long disability, with no significant reduction in life expectancy, affecting a diverse range of cognitive and social functions including memory, task planning and execution, impulse control, social interactions, personality changes and depression. Following traumatic brain injury acquired deficits can lead to problems with resumption of aspects of daily life, particularly in terms of returning to work and interpersonal relationships.
The initial injury triggers a secondary cascade of metabolic, neurochemical and cellular changes within the brain, primarily aimed at limiting damage and stimulating repair. Paradoxically prolonged secondary cascade mechanisms, including haemorrhage, oedema, neuroinflammation and axonal injury, results in exacerbation of deficits observed. The heterogeneous on-going nature of the secondary cascade presents clinicians with opportunities to intervene in an attempt to limit neuronal damage. A large body of nutritional research has been focused on addressing the hypermetabolic and catabolic states created by secondary cascade processes in the acute stage. Addressing these demands has played a significant role in reducing mortality and infection rates following head injury, however there has not been the same depth of research investigating the post-acute period (once individuals are discharged from hospital).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Traumatic Brain Injury | Dietary Supplement: Swisse Womens 50+ Ultivite Multivitamin Dietary Supplement: Holland and Barrett Triple Strength Omega-3 Fish Oil | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | Micronutrient Intervention Effects on Cognitive Outcomes in Post-Acute Traumatic Brain Injury |
Actual Study Start Date : | October 1, 2017 |
Actual Primary Completion Date : | April 18, 2020 |
Actual Study Completion Date : | April 18, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Multivitamin
Swisse Womens 50+ Ultivite Multivitamin. Once daily.
|
Dietary Supplement: Swisse Womens 50+ Ultivite Multivitamin
Single tablet taken once daily Dietary Supplement: Holland and Barrett Triple Strength Omega-3 Fish Oil Single capsule taken once daily |
Experimental: Omega-3 Fatty Acids
Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
|
Dietary Supplement: Swisse Womens 50+ Ultivite Multivitamin
Single tablet taken once daily Dietary Supplement: Holland and Barrett Triple Strength Omega-3 Fish Oil Single capsule taken once daily |
No Intervention: Control
Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
|
- Performance on cognitive test measures (a battery of standardized tests; memory, executive function, social cognition, general intelligence, learning and processing speed) [ Time Frame: Three time points: baseline (T1), 8 weeks (T2) and 22 weeks (T3) ]Analysis of change in cognitive test battery results between each time point (T2 minus T1. T3 minus T2. T3 minus T1)
- Average dietary intake of micronutrients and fatty acids [ Time Frame: Data collected at four time points (3 day diaries) during participant's involvement in the study via participants filling in paper food diary ]Analysis of dietary intake via Nutritics software (https://www.nutritics.com/p/references), average intake value for each micronutrient supplied by software output. This will be compared to recommended daily amounts to evaluate levels of sufficiency/insufficiency in each participant.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- First and only traumatic brain injury.
- Complex mild to moderate injury.
- 3-24 months post-injury
Exclusion Criteria:
- Unable to give informed consent.
- Already taking micronutrient/fatty acid supplements.
- Hemianopia
- Hemiplegia.
- Pregnant or breastfeeding.
- Diagnosed with clinically low blood pressure, diabetes, or disease of neurodegeneration.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03032302
United Kingdom | |
Sheffield Hallam University | |
Sheffield, South Yorkshire, United Kingdom, S10 2BQ |
Study Director: | Lynne A Barker, PhD | Sheffield Hallam University |
Publications:
Responsible Party: | Sheffield Hallam University |
ClinicalTrials.gov Identifier: | NCT03032302 |
Other Study ID Numbers: |
STH19529 |
First Posted: | January 26, 2017 Key Record Dates |
Last Update Posted: | October 22, 2020 |
Last Verified: | October 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
TBI |
Brain Injuries Brain Injuries, Traumatic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries |